{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T06:09:44Z","timestamp":1765778984161,"version":"3.48.0"},"reference-count":29,"publisher":"CSIRO Publishing","issue":"6","license":[{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"vor","delay-in-days":1365,"URL":"https:\/\/doi.org\/10.1071\/journalslicense"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,12,9]]},"abstract":"\n Objective<\/jats:title>\n This study investigated antibiotic prophylaxis (AP) guideline adherence and the cardiac implantable electronic device (CIED) infection rate in two major Australian public teaching hospitals.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n In a retrospective observational study, the medical records of patients who underwent CIED procedures between January and December 2017 were reviewed (Hospital A, n = 400 procedures; Hospital B, n = 198 procedures). Adherence to AP guidelines was assessed regarding drug, dose, timing, route and frequency. Infection was identified using follow-up documentation.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n AP was administered in 582 of 598 procedures (97.3%). Full guideline adherence was observed in 33.9% of procedures (203\/598) and differed significantly between Hospitals A and B (47.3% vs 7.1%, respectively; P &lt; 0.001). Common reasons for non-adherence were the timing of administration (42.3% vs 60.6% non-adherent in Hospitals A and B, respectively; P &lt; 0.001) and repeat dosing (19.3% vs 78.8% non-adherent in Hospitals A and B, respectively; P &lt; 0.001). Twenty infections were identified over 626.6 patient-years of follow-up (mean (\u00b1s.d.) follow-up 1.0 \u00b1 0.3 years). The infection rate was 3.19 per 100 patient-years (P = 0.99 between hospitals). Two devices were removed due to infection; no patients died from CIED infection.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Although the rate of serious CIED infection was low, there was evidence of highly variable and suboptimal antibiotic use, and potential overuse of AP.<\/jats:p>\n <\/jats:sec>\n \n What is known about the topic?<\/jats:title>\n Previous Australian studies have revealed high rates of inappropriate surgical AP. CIED infections are potentially life threatening, but can be avoided through effective use of AP. However, prolonged durations of AP in this setting may also result in complications, including Clostridioides difficile infection.<\/jats:p>\n <\/jats:sec>\n \n What does this paper add?<\/jats:title>\n This study, the first to our knowledge to focus specifically on adherence to Australian guidelines for AP in CIED procedures, highlighted several common issues between AP in this setting and surgical and procedural AP more broadly. \u2018Early\u2019 and \u2018late\u2019 dose administration and extended post-procedural AP were common. Only 34% of prescriptions fully adhered to the guidelines; practices varied significantly between the two hospitals.<\/jats:p>\n <\/jats:sec>\n \n What are the implications for practitioners?<\/jats:title>\n There is a clear need for institution-specific antimicrobial stewardship strategies to optimise AP in CIED procedures, aligned with the Antimicrobial Stewardship Clinical Care Standard. Patients are being placed at potentially avoidable risk of both complications of extended durations of AP and CIED infection, although the rate of serious CIED infection was low. A standardised approach to surveillance of CIED infections and prospective multisite audits of AP in CIED procedures using a validated tool, such as the Surgical National Antimicrobial Prescribing Survey, are recommended to better inform evidence-based practice. Potential strategies to optimise guideline adherence include prescribing support in patients with immediate penicillin hypersensitivity or methicillin-resistant Staphylococcus aureus colonisation, optimising the in-patient location of drug administration to promote timely dosing, limiting inappropriate post-procedural prophylaxis and routine S. aureus screening and decolonisation.<\/jats:p>\n <\/jats:sec>","DOI":"10.1071\/ah21046","type":"journal-article","created":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T00:38:38Z","timestamp":1630543118000},"page":"761-770","source":"Crossref","is-referenced-by-count":0,"title":["Adherence to antimicrobial prophylaxis guidelines in cardiac implantable electronic device procedures in two Australian teaching hospitals"],"prefix":"10.1071","volume":"45","author":[{"given":"Monique","family":"Almonte","sequence":"first","affiliation":[{"name":"ASchool of Pharmacy and Biomedical Sciences, Curtin University, Bentley, WA, Australia. Email: moniquealmonte1@gmail.com"},{"name":"GPresent address: Northlands Pharmacy, Balcatta, WA, Australia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taylor","family":"Huston","sequence":"additional","affiliation":[{"name":"ASchool of Pharmacy and Biomedical Sciences, Curtin University, Bentley, WA, Australia. Email: moniquealmonte1@gmail.com"},{"name":"HPresent address: TerryWhite Chemmart Leeming, Leeming, WA, Australia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sok Ling","family":"Yee","sequence":"additional","affiliation":[{"name":"ASchool of Pharmacy and Biomedical Sciences, Curtin University, Bentley, WA, Australia. Email: moniquealmonte1@gmail.com"},{"name":"IPresent address: Pharmacy Alliance, Albany, WA, Australia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roya","family":"Karimaei","sequence":"additional","affiliation":[{"name":"ASchool of Pharmacy and Biomedical Sciences, Curtin University, Bentley, WA, Australia. Email: moniquealmonte1@gmail.com"},{"name":"JPresent address: Pharmacy 777 Lynwood, Lynwood, WA, Australia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9973-217X","authenticated-orcid":true,"given":"Adam","family":"Hort","sequence":"additional","affiliation":[{"name":"BPharmacy Department, Fiona Stanley Hospital, South Metropolitan Health Service, Murdoch, WA, Australia. Email: adam.hort@health.wa.gov.au"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6525-1084","authenticated-orcid":true,"given":"Matthew","family":"Rawlins","sequence":"additional","affiliation":[{"name":"BPharmacy Department, Fiona Stanley Hospital, South Metropolitan Health Service, Murdoch, WA, Australia. Email: adam.hort@health.wa.gov.au"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Seet","sequence":"additional","affiliation":[{"name":"CPharmacy Department, Sir Charles Gairdner Hospital, North Metropolitan Health Service, Nedlands, WA, Australia. Email: jason.seet@health.wa.gov.au"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zachiah","family":"Nizich","sequence":"additional","affiliation":[{"name":"CPharmacy Department, Sir Charles Gairdner Hospital, North Metropolitan Health Service, Nedlands, WA, Australia. Email: jason.seet@health.wa.gov.au"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duncan","family":"McLellan","sequence":"additional","affiliation":[{"name":"DInfectious Diseases Department, Fiona Stanley Hospital, South Metropolitan Health Service, Murdoch, WA, Australia. Email: Duncan.McLellan@health.wa.gov.au"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Stobie","sequence":"additional","affiliation":[{"name":"EDepartment of Cardiovascular Medicine, North Metropolitan Health Service, Nedlands, WA, Australia. Email: paul.stobie@health.wa.gov.au"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petra","family":"Czarniak","sequence":"additional","affiliation":[{"name":"ASchool of Pharmacy and Biomedical Sciences, Curtin University, Bentley, WA, Australia. Email: moniquealmonte1@gmail.com"},{"name":"FPresent address: Curtin Medical School, Curtin University, Bentley, WA, Australia. Email: P.Czarniak@curtin.edu.au"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2477-2190","authenticated-orcid":true,"given":"Leanne","family":"Chalmers","sequence":"additional","affiliation":[{"name":"ASchool of Pharmacy and Biomedical Sciences, Curtin University, Bentley, WA, Australia. Email: moniquealmonte1@gmail.com"},{"name":"FPresent address: Curtin Medical School, Curtin University, Bentley, WA, Australia. Email: P.Czarniak@curtin.edu.au"},{"name":"KCorresponding author. Email: leanne.chalmers@curtin.edu.au"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"67","published-online":{"date-parts":[[2021,9,2]]},"reference":[{"key":"2025121501051521200_R1","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1111\/j.1540-8159.2009.02670.x","article-title":"Implantation trends and patient profiles for pacemakers and implantable cardioverter defibrillators in the United States: 1993\u20132006.","volume":"33","author":"Kurtz","year":"2010","journal-title":"Pacing Clin Electrophysiol"},{"key":"2025121501051521200_R2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.010869","article-title":"Sex differences in acute complications of cardiac implantable electronic devices: Implications for patient safety.","volume":"8","author":"Moore","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"2025121501051521200_R3","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1093\/jac\/dku383","article-title":"Guidelines for the diagnosis, prevention and management of implantable cardiac electronic device infection. Report of a joint Working Party project on behalf of the British Society for Antimicrobial Chemotherapy (BSAC, host organization), British Heart Rhythm Society (BHRS), British Cardiovascular Society (BCS), British Heart Valve Society (BHVS) and British Society for Echocardiography (BSE).","volume":"70","author":"Sandoe","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2025121501051521200_R4","doi-asserted-by":"publisher","first-page":"3098","DOI":"10.1016\/j.jacc.2018.09.068","article-title":"Prevention of Arrhythmia Device Infection Trial: The PADIT Trial.","volume":"72","author":"Krahn","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2025121501051521200_R5","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1111\/j.1540-8159.2012.03506.x","article-title":"Antibiotics and antiseptics to prevent infection in cardiac rhythm management device implantation surgery.","volume":"35","author":"Darouiche","year":"2012","journal-title":"Pacing Clin Electrophysiol"},{"key":"2025121501051521200_R6","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1093\/eurheartj\/ehv060","article-title":"Infected cardiac-implantable electronic devices: prevention, diagnosis, and treatment.","volume":"36","author":"Nielsen","year":"2015","journal-title":"Eur Heart J"},{"key":"2025121501051521200_R7","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.hrthm.2017.03.019","article-title":"Cardiac implantable electronic device infections: Who is at greatest risk?","volume":"14","author":"Joy","year":"2017","journal-title":"Heart Rhythm"},{"key":"2025121501051521200_R8","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1016\/j.hrthm.2015.06.043","article-title":"Preventing cardiac implantable electronic device infections.","volume":"12","author":"Padfield","year":"2015","journal-title":"Heart Rhythm"},{"key":"2025121501051521200_R9","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1111\/pace.12403","article-title":"A 19-year study on pacemaker-related infections: A claim for using postoperative antibiotics.","volume":"37","author":"Senaratne","year":"2014","journal-title":"Pacing Clin Electrophysiol"},{"key":"2025121501051521200_R10","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1161\/CIRCEP.108.795906","article-title":"Efficacy of antibiotic prophylaxis before the implantation of pacemakers and cardioverter-defibrillators: results of a large, prospective, randomized, double-blinded, placebo-controlled trial.","volume":"2","author":"de Oliveira","year":"2009","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"2025121501051521200_R11"},{"key":"2025121501051521200_R12","unstructured":"Western Australian Therapeutics Advisory Group. Surgical antibiotic prophylaxis guideline: adults. Perth: Government of Western Australia; 2014. Available at: https:\/\/ww2.health.wa.gov.au\/~\/media\/Files\/Corporate\/general%20documents\/WATAG\/Surgical-Antibiotic-Prophylaxis-Guideline.pdf [verified 31 July 2019]"},{"key":"2025121501051521200_R13","unstructured":"Australian Commission on Safety and Quality in Health Care (ACSQHC). AURA 2019: third Australian report on antimicrobial use and resistance in human health. Sydney: ACSQHC; 2019. Available at: https:\/\/www.safetyandquality.gov.au\/our-work\/antimicrobial-resistance\/antimicrobial-use-and-resistance-australia-surveillance-system\/aura-2019"},{"key":"2025121501051521200_R14","unstructured":"National Centre for Antimicrobial Stewardship and Australian Commission on Safety and Quality in Health Care. Surgical prophylaxis prescribing in Australian hospitals. Results of the 2019 Surgical National Antimicrobial Prescribing Survey. Sydney: ACSQHC; 2020. Available at: https:\/\/www.safetyandquality.gov.au\/publications-and-resources\/resource-library\/surgical-national-antimicrobial-prescribing-survey-results-2019-survey"},{"key":"2025121501051521200_R15","unstructured":"Australian Commission on Safety and Quality in Health Care (ACSQHC). Surgical antimicrobal prophylaxis. Sydney: ACSQHC; 2019. Available at: https:\/\/www.safetyandquality.gov.au\/our-work\/antimicrobial-stewardship\/surgical-antimicrobial-prophylaxis"},{"key":"2025121501051521200_R16","unstructured":"Australian Commission on Safety and Quality in Health Care (ACSQHC). Antimicrobial stewardship clinical care standard. Sydney: ACSQHC; 2020. Available at: https:\/\/www.safetyandquality.gov.au\/our-work\/clinical-care-standards\/antimicrobial-stewardship-clinical-care-standard"},{"key":"2025121501051521200_R17","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1017\/ice.2018.170","article-title":"Prolonged antimicrobial prophylaxis following cardiac device procedures increases preventable harm: insights from the VA CART program.","volume":"39","author":"Asundi","year":"2018","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2025121501051521200_R18","unstructured":"SNOMED International. SNOMED CT: a five-step briefing. London: SNOMED International; 2021. Available at: https:\/\/www.snomed.org\/snomed-ct\/five-step-briefing"},{"key":"2025121501051521200_R19"},{"key":"2025121501051521200_R20","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.acvd.2011.02.003","article-title":"Cardiac implantable devices: Surveillance of surgical site infections and assessment of professional practices.","volume":"104","author":"Metais","year":"2011","journal-title":"Arch Cardiovasc Dis"},{"key":"2025121501051521200_R21","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1161\/CIRCULATIONAHA.109.192665","article-title":"Update on cardiovascular implantable electronic device infections and their management: a scientific statement from the American Heart Association.","volume":"121","author":"Baddour","year":"2010","journal-title":"Circulation"},{"key":"2025121501051521200_R22","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1089\/sur.2017.119","article-title":"Antibiotic prescribing practices for prevention of surgical site infections in Australia: increased uptake of national guidelines after surveillance and reporting and impact on infection rates.","volume":"18","author":"Bull","year":"2017","journal-title":"Surg Infect (Larchmt)"},{"key":"2025121501051521200_R23","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.jacep.2017.01.013","article-title":"Periprocedural antibiotic prophylaxis for cardiac implantable electrical device procedures: results from a Heart Rhythm Society Survey.","volume":"3","author":"Basil","year":"2017","journal-title":"JACC Clin Electrophysiol"},{"key":"2025121501051521200_R24","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1111\/pace.13592","article-title":"Postoperative antibiotic prophylaxis in the prevention of cardiac implantable electronic device infection.","volume":"42","author":"Madadi","year":"2019","journal-title":"Pacing Clin Electrophysiol"},{"key":"2025121501051521200_R25"},{"key":"2025121501051521200_R26","unstructured":"Healthcare Infection Surveillance WA (HISWA), Communicable Disease Control Directorate, Department of Health, Western Australia. Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA). Perth: Department of Health, Western Australia; 2019. Available at: https:\/\/ww2.health.wa.gov.au\/Reports-and-publications\/ca-mrsa\/data?report=mrsa_data"},{"key":"2025121501051521200_R27","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1086\/676022","article-title":"Strategies to prevent surgical site infections in acute care hospitals: 2014 update.","volume":"35","author":"Anderson","year":"2014","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2025121501051521200_R28","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa0808939","article-title":"Preventing surgical-site infections in nasal carriers of Staphylococcus aureus.","volume":"362","author":"Bode","year":"2010","journal-title":"N Engl J Med"},{"key":"2025121501051521200_R29","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s11886-016-0733-x","article-title":"Prevention, diagnosis, and treatment of cardiac implantable electronic device infections.","volume":"18","author":"Leung","year":"2016","journal-title":"Curr Cardiol Rep"}],"container-title":["Australian Health Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/connectsci.au\/ah\/article-pdf\/45\/6\/761\/439988\/ah21046.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/connectsci.au\/ah\/article-pdf\/45\/6\/761\/439988\/ah21046.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T06:05:24Z","timestamp":1765778724000},"score":1,"resource":{"primary":{"URL":"https:\/\/connectsci.au\/ah\/article\/45\/6\/761\/71008\/Adherence-to-antimicrobial-prophylaxis-guidelines"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,2]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12,9]]}},"URL":"https:\/\/doi.org\/10.1071\/ah21046","relation":{},"ISSN":["0156-5788","1449-8944"],"issn-type":[{"type":"print","value":"0156-5788"},{"type":"electronic","value":"1449-8944"}],"subject":[],"published":{"date-parts":[[2021,9,2]]}}}